• Loading stock data…

biotech news

Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

COPENHAGEN, Denmark, December 8, 2022 - Bavarian Nordic A/S (OMX: BAVA) has today received information about the following transactions of the company's shares/related securities by persons holding … [Read more...] about Report of transactions of shares and related securities of Bavarian Nordic by persons holding managerial responsibilities and/or persons/companies closely associated with such

Indberetning af ledende medarbejdere og disses naertst?endes transaktioner med Bavarian Nordic aktier og tilknyttede vaerdipapirer

K?BENHAVN, Danmark, 8. december 2022 - Bavarian Nordic A/S (OMX: BAVA) har dags dato modtaget oplysninger om f?lgende transaktioner med selskabets aktie/tilknyttede vaerdipapirer, foretaget af ledende … [Read more...] about Indberetning af ledende medarbejdere og disses naertst?endes transaktioner med Bavarian Nordic aktier og tilknyttede vaerdipapirer

New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

COPENHAGEN, Denmark, December 8, 2022 - Bavarian Nordic A/S (OMX: BAVA) announced today that the Board of Directors has decided to issue warrants to members of the Executive Management and selected … [Read more...] about New Incentive Program Established for Members of Executive Management and Selected Employees in Bavarian Nordic

Bavarian Nordic ivaerksaetter nyt incitamentsprogram for koncernledelsen og udvalgte medarbejdere

K?BENHAVN, Danmark, 8. december 2022 - Bavarian Nordic A/S (OMX: BAVA) meddelte i dag, at bestyrelsen har besluttet at udstede tegningsoptioner til koncernledelsen og udvalgte medarbejdere i Bavarian … [Read more...] about Bavarian Nordic ivaerksaetter nyt incitamentsprogram for koncernledelsen og udvalgte medarbejdere

Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

Bivalent vaccine authorized as third 3-ug dose in the three-dose primary seriesConsistent COVID-19 hospitalization rates in this age group coupled with an overall surge in respiratory illnesses among … [Read more...] about Pfizer and BioNTech Receive U.S. FDA Emergency Use Authorization for Omicron BA.4/BA.5-Adapted Bivalent COVID-19 Vaccine in Children Under 5 Years

T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial Therapy

LEXINGTON, Mass., Dec. 08, 2022 (GLOBE NEWSWIRE) -- T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistant genes, today announced the … [Read more...] about T2 Biosystems Highlights Peer-Reviewed Article Linking COVID-19 and Sepsis and Underscoring CDC Call for Adoption of Early and Accurate Microbial Diagnosis to Guide Targeted Initial Antimicrobial Therapy

Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE

IRVINE, Calif., Dec. 08, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA) (the “Company”) received clearance from the Kingdom of Saudi Arabia Food and Drug Administration (KFDA), and the … [Read more...] about Biomerica Receives KFDA and Ministry of Health Approval for Colorectal Screening and Breast Screening Tests in Saudi Arabia and UAE

INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune(TM)

Boca Raton, Florida, Dec. 08, 2022 (GLOBE NEWSWIRE) -- INmune Bio, Inc. (NASDAQ: INMB) ("INMB" or "the Company"), a clinical-stage immunology company focused on developing treatments that harness … [Read more...] about INmune Bio, Inc. Data at ASH Highlight Innovative Natural Killer Cell Therapeutic Platform Showing 100+ Day Persistence of Cancer Killing Memory Like NK Cells in Patients with AML/MDS Following Treatment with INKmune(TM)